We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

17 hedge funds and large institutions have $6.16M invested in Outlook Therapeutics in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

6% more capital invested

Capital invested by funds: $5.79M → $6.16M (+$369K)

6% more funds holding

Funds holding: 16 → 17 (+1)

0.03% less ownership

Funds ownership: 0.15% → 0.12% (-0.03%)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.42%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
3
Increased
3
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$33.1K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$25.6K
3
SM
Sabby Management
Florida
+$20.7K
4
TSS
Two Sigma Securities
New York
+$13.5K
5
Bank of America
Bank of America
North Carolina
+$11.5K

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$837K
2
CAM
Cormorant Asset Management
Massachusetts
-$465K
3
Millennium Management
Millennium Management
New York
-$31K
4
Wells Fargo
Wells Fargo
California
-$11.3K
5
Morgan Stanley
Morgan Stanley
New York
-$6.37K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$3.27M +$20.7K +114 +0.8%
ACA
2
Avoro Capital Advisors
New York
$936K – – –
CAM
3
Cormorant Asset Management
Massachusetts
$814K -$465K -2,554 -41%
Vanguard Group
4
Vanguard Group
Pennsylvania
$418K +$25.6K +141 +8%
MWNA
5
Marshall Wace North America
New York
$262K – – –
BCM
6
Bridgeway Capital Management
Texas
$189K – – –
PAM
7
Panagora Asset Management
Massachusetts
$83K -$5.09K -28 -7%
BlackRock
8
BlackRock
New York
$41K -$2K -11 -5%
ACP
9
Acuta Capital Partners
California
$40K – – –
VF
10
Virtu Financial
New York
$40K +$33.1K +182 New
Morgan Stanley
11
Morgan Stanley
New York
$22K -$6.37K -35 -26%
TSS
12
Two Sigma Securities
New York
$16K +$13.5K +74 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$15K – – –
Bank of America
14
Bank of America
North Carolina
$14K +$11.5K +63 New
UBS Group
15
UBS Group
Switzerland
$4K +$546 +3 +25%
ASN
16
Advisory Services Network
Georgia
$3K – – –
PA
17
Perceptive Advisors
New York
– -$837K -5,237 Closed
Millennium Management
18
Millennium Management
New York
– -$31K -196 Closed
Wells Fargo
19
Wells Fargo
California
– -$11.3K -62 -98%

OTLK Hedge Fund Activity: Q3 2017 in Review

17 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q3 2017, worth a combined $6.16M — up 6.4% from $5.79M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new OTLK positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 5 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $33.1K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $837K sold.

  • 17 institutional investors held Outlook Therapeutics (OTLK) as of Q3 2017, up from 16 in Q2 2017.
  • Funds reported $6.16M of Outlook Therapeutics stock for Q3 2017, up 6.4% quarter-over-quarter.
  • 3 funds opened new Outlook Therapeutics positions in Q3 2017 and 2 closed out, a net change of +1 holder.
  • The largest Outlook Therapeutics buyer in Q3 2017 was Virtu Financial, an estimated $33.1K added.
  • The largest Outlook Therapeutics seller in Q3 2017 was Perceptive Advisors, an estimated $837K sold.

Based on aggregated 13F filings for Q3 2017.